PubRank

R Korbut

Author PubWeight™ 67.49‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 2003 2.89
2 Corticosteroids inhibit prostaglandin release from perfused mesenteric blood vessels of rabbit and from perfused lungs of sensitized guinea pig. Prostaglandins 1975 2.45
3 Adipocytokines - novel link between inflammation and vascular function? J Physiol Pharmacol 2006 2.21
4 Generation of prostacyclin by lungs in vivo and its release into the arterial circulation. Nature 1978 2.10
5 Mouse models of experimental atherosclerosis. J Physiol Pharmacol 2004 1.68
6 Prostacyclin is a circulating hormone. Nature 1978 1.60
7 Immediate release of a nitric oxide-like factor from bovine aortic endothelial cells by Escherichia coli lipopolysaccharide. Proc Natl Acad Sci U S A 1990 1.54
8 Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet 1978 1.53
9 On the mechanism of antithrombotic action of flavonoids. Biochem Pharmacol 1987 1.43
10 In vivo method for quantitation for anti-platelet potency of drugs. Naunyn Schmiedebergs Arch Pharmacol 1978 1.17
11 Effects of prolonged oral supplementation with l-arginine on blood pressure and nitric oxide synthesis in preeclampsia. Eur J Clin Invest 2005 1.14
12 The use of oxyhaemoglobin to explore the events underlying inhibition of platelet aggregation induced by NO or NO-donors. Br J Pharmacol 1990 1.11
13 Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. Eur J Clin Invest 2006 1.09
14 Perivascular adipose tissue as a messenger of the brain-vessel axis: role in vascular inflammation and dysfunction. J Physiol Pharmacol 2007 1.08
15 Effect of curcumin on atherosclerosis in apoE/LDLR-double knockout mice. J Physiol Pharmacol 2005 1.06
16 Lipopolysaccharide increases release of a nitric oxide-like factor from endothelial cells. Eur J Pharmacol 1989 1.04
17 Prostacyclin (PGI2) and thromboxane A2 interaction in vivo. Regulation by aspirin and relationship with anti-thrombotic therapy. Thromb Res 1978 1.04
18 Sodium nitroprusside modulates the fibrinolytic system in the rabbit. Br J Pharmacol 1990 0.97
19 Selective inhibition of thromboxane A2 biosynthesis in blood platelets. Nature 1977 0.95
20 Effects of novel plant antioxidants on platelet superoxide production and aggregation in atherosclerosis. J Physiol Pharmacol 2006 0.92
21 Endothelins release tissue plasminogen activator and prostanoids. Eur J Pharmacol 1990 0.90
22 Prolongation of fibrinolytic activity of tissue plasminogen activator by nitrovasodilators. Lancet 1990 0.89
23 Fibrinolytic activity of 6-keto-prostaglandin E1. Thromb Haemost 1983 0.87
24 The current view on the role of leukotrienes in atherogenesis. J Physiol Pharmacol 2010 0.87
25 Kaempferol, but not resveratrol inhibits angiotensin converting enzyme. J Physiol Pharmacol 2008 0.86
26 The effect of montelukast on atherogenesis in apoE/LDLR-double knockout mice. J Physiol Pharmacol 2008 0.86
27 Inhibition of nuclear factor-kappaB attenuates artherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol 2005 0.85
28 Superoxide dismutase activity and expression in human venous and arterial bypass graft vessels. J Physiol Pharmacol 2005 0.84
29 Angiotensin-(1-7) receptor Mas agonist ameliorates progress of atherosclerosis in apoE-knockout mice. J Physiol Pharmacol 2012 0.83
30 Thrombolytic action of ticlopidine: possible mechanisms. Eur J Pharmacol 1996 0.83
31 Respiratory movements alter the generation of prostacyclin and thromboxane A2 in isolated rat lungs: the influence of arachidonic acid-pathway inhibitors on the ratio between pulmonary prostacyclin and thromboxane A2. Prostaglandins 1981 0.83
32 Angiotensinogen metabolism in rat aorta: robust formation of proangiotensin-12. J Physiol Pharmacol 2010 0.82
33 Interaction between NO donors and iloprost in human vascular smooth muscle, platelets, and leukocytes. J Cardiovasc Pharmacol 1989 0.81
34 Effects of nitric oxide and prostacyclin on deformability and aggregability of red blood cells of rats ex vivo and in vitro. J Physiol Pharmacol 1999 0.81
35 Production of prostacyclin and prostaglandin E2 in resting and IL-1beta-stimulated A549, HUVEC and hybrid EA.HY 926 cells. J Physiol Pharmacol 2006 0.81
36 Third-stage nematode larvae of Contracaecum osculatum from Baltic cod (Gadus morhua) elicit eosinophilic granulomatous reactions when penetrating the stomach mucosa of pigs. Parasitol Res 2015 0.81
37 Lungs as a generator of prostacyclin--hypothesis on physiological significance. Naunyn Schmiedebergs Arch Pharmacol 1978 0.80
38 Endothelial secretogogues and deformability of erythrocytes. J Physiol Pharmacol 2002 0.80
39 AVE 0991-angiotensin-(1-7) receptor agonist, inhibits atherogenesis in apoE-knockout mice. J Physiol Pharmacol 2010 0.80
40 Interaction between stimulators of adenylate and guanylate cyclases in human leukocytes, platelets and arteries. Int J Tissue React 1989 0.80
41 A possible role of thromboxane A2 (TXA2) and prostacyclin (PGI2) in circulation. Acta Biol Med Ger 1978 0.79
42 NADPH oxidase and uncoupled nitric oxide synthase are major sources of reactive oxygen species in oral squamous cell carcinoma. Potential implications for immune regulation in high oxidative stress conditions. J Physiol Pharmacol 2008 0.79
43 The role of nitric oxide in regulation of deformability of red blood cells in acute phase of endotoxaemia in rats. J Physiol Pharmacol 1997 0.79
44 Treatment with L-arginine is likely to stimulate generation of nitric oxide in patients with peripheral arterial obstructive disease. Wien Klin Wochenschr 1996 0.79
45 The effect of nebivolol on atherogenesis in apoE-knockout mice. J Physiol Pharmacol 2009 0.79
46 Measurement of angiotensin metabolites in organ bath and cell culture experiments by liquid chromatography - electrospray ionization - mass spectrometry (LC-ESI-MS). J Physiol Pharmacol 2007 0.79
47 Prostacyclin therapy in peripheral arterial disease. Thromb Res 1981 0.79
48 beta-Pyridylcarbinol (Ronicol) releases a prostacyclin-like substance into arterial blood of patients with arteriosclerosis obliterans. Pharmacol Res Commun 1983 0.78
49 Influence of pre-operative ketoprofen administration (preemptive analgesia) on analgesic requirement and the level of prostaglandins in the early postoperative period. Pol J Pharmacol 2004 0.78
50 Release of a prostaglandin E-like substance into mixed venous blood during endotoxin hypotension in cats. Pol J Pharmacol Pharm 1975 0.78
51 Effect of L-arginine on plasminogen-activator inhibitor in hypertensive patients with hypercholesterolemia. N Engl J Med 1993 0.78
52 The current view on biological potency of cationically modified chitosan. J Physiol Pharmacol 2014 0.78
53 BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol 2007 0.78
54 Angiotensin metabolism in rat stomach wall: prevalence of angiotensin-(1-7) formation. J Physiol Pharmacol 2009 0.77
55 Secretory dysfunction of vascular endothelium limits the effect of angiotensin converting enzyme inhibitor quinapril on aggregation of erythrocytes in experimental hypertension. J Physiol Pharmacol 2003 0.77
56 Effect of ticlopidine on streptokinase-induced thrombolysis in rats. Wien Klin Wochenschr 1999 0.77
57 The influence of angiotensin-(1-7) peptidomimetic (AVE 0991) and nebivolol on angiotensin I metabolism in aorta of apoE-knockout mice. J Physiol Pharmacol 2013 0.76
58 Endotoxaemia in rats: role of leukocyte sequestration in rapid pulmonary nitric oxide synthase-2 expression. J Physiol Pharmacol 2005 0.76
59 De-aggregatory action of prostacyclin in vivo and its enhancement by theophylline. Prostaglandins 1978 0.76
60 Inhibition of NOS-2 induction in LPS-stimulated J774.2 cells by 1, 5-isoquinolinediol, an inhibitor of PARP. J Physiol Pharmacol 2006 0.76
61 The effect of doxycycline on atherogenesis in apoE-knockout mice. J Physiol Pharmacol 2011 0.76
62 The mechanism of anti-thrombotic, thrombolytic and fibrinolytic actions of camonagrel--a new thromboxane synthase inhibitor. Wien Klin Wochenschr 1995 0.76
63 Mass-spectrometric evidence for spontaneous and angiotensin-induced generation of prostacyclin by perfused cat lungs. Prostaglandins 1980 0.76
64 On the mechanism of antiaggregatory effect of myricetin. Pol J Pharmacol Pharm 1989 0.76
65 [Wound repair]. Postepy Hig Med Dosw 1998 0.76
66 Angiotensinogen and angiotensin-converting enzyme mRNA decrease and AT1 receptor mRNA and protein increase in epididymal fat tissue accompany age-induced elevation of adiposity and reductions in expression of GLUT4 and peroxisome proliferator-activated receptor (PPARγ). J Physiol Pharmacol 2011 0.76
67 Influence of cadmium intoxication on thromboresistance of vascular endothelium in rabbits. J Physiol Pharmacol 1998 0.76
68 Release of prostacyclin from the human pulmonary vascular bed in response to cholinergic stimulation. Naunyn Schmiedebergs Arch Pharmacol 1984 0.75
69 Bioassay of histamine in the presence of prostaglandins. Br J Pharmacol 1976 0.75
70 Bioassay of prostaglandins in the presence of high concentrations of catecholamines. Pol J Pharmacol Pharm 1976 0.75
71 Anti-aggregatory prostanoids. Part I. Acta Physiol Pol 1986 0.75
72 The involvement of adhesion molecules and lipid mediators in the adhesion of human platelets to eosinophils. J Physiol Pharmacol 2005 0.75
73 Perindoprilat changes ANG (1-9) production in renal arteries isolated from young spontaneously hypertensive rats after ANG I incubation. Physiol Res 2016 0.75
74 Almitrine increases plasma fibrinolytic activity through the release of prostacyclin from lungs into circulation. Pharmacol Res Commun 1982 0.75
75 [New method of biologically assaying active substances in mixtures using the cascade technic of washing isolated detector organs]. Folia Med Cracov 1977 0.75
76 Effect of aspirin on cysteinyl leukotrienes production by eosinophils co-cultured with epithelial cells. J Physiol Pharmacol 2004 0.75
77 Regulatory role of prostaglandins in the vascular system. Mater Med Pol 1976 0.75
78 Prostacyclin and atherosclerosis--experimental and clinical approaches. Adv Exp Med Biol 1988 0.75
79 [Role of arachidonic acid metabolites in the mediation of pain]. Postepy Hig Med Dosw 1987 0.75
80 Reversal of platelet aggregation by prostacyclin. Pharmacol Res Commun 1978 0.75
81 [Prostacyclin, EDRF and arteriosclerosis]. Przegl Lek 1989 0.75
82 Prostacyclin and thromboxane A2 release in isolated rat lungs. Prostaglandins 1982 0.75
83 Eicosanoid balance at early stages of experimental atherosclerosis. Its relationship with plasma fibrinolytic activity and platelet aggregation. Agents Actions Suppl 1986 0.75
84 Fibrinolytic activity and the effects of beta-pyridylcarbinol (Ronicol) in patients with arteriosclerosis obliterans. Thromb Haemost 1983 0.75
85 Stimulatory cholinergic effect on the release of antiaggregatory activity into the circulation of cat and man and its modification by beta-adrenergic antagonists. Eur J Clin Invest 1985 0.75
86 Prostaglandin feedback mechanism limits vasoconstrictor action of norepinephrine in perfused rabbit ear. Experientia 1975 0.75
87 Endogenous mechanisms that regulate prostacyclin release. Adv Prostaglandin Thromboxane Res 1980 0.75
88 [A case of penetrating chest wound by a tube with rupture of the lobar bronchus]. Pol Tyg Lek 1966 0.75
89 The influence of hydrocortisone and indomethacin on the release of prostaglandin-like substances during circulatory shock in cats, which was induced by an intravenous administration of rabbit blood. Pharmacol Res Commun 1978 0.75
90 Anti-aggregatory prostanoids. Part II. Acta Physiol Pol 1986 0.75
91 Endogenous mechanisms which regulate prostacyclin release. Haemostasis 1979 0.75
92 Novel concept in the mechanism of injury and protection of gastric mucosa: role of renin-angiotensin system and active metabolites of angiotensin. Curr Med Chem 2012 0.75
93 Significant deterioration of anti-atherogenic efficacy of nebivolol in a double (apolipoprotein E and endothelial nitric oxide synthase) knockout mouse model of atherosclerosis in comparison to single (apolipoprotein E) knockout model. J Physiol Pharmacol 2014 0.75
94 [Endogenous mechanisms regulating the release of prostacyclin in circulating blood]. Folia Med Cracov 1984 0.75
95 Formation of lipoxygenase and cyclooxygenase metabolites of arachidonic acid by brain tissue. Biomed Biochim Acta 1984 0.75
96 A new endocrine-like function of lungs: generation of prostacyclin. Mater Med Pol 1979 0.75
97 [Effect of indomethacin on the cardionecrotropic action of isoprenaline in rats]. Folia Med Cracov 1975 0.75
98 Vasodilatory effect and endothelial integrity in papaverine- and milrinone-treated human radial arteries. J Physiol Pharmacol 2013 0.75
99 Crossroads of L-arginine/arachidonate metabolism. Thromb Haemost 1997 0.75
100 Effect of glucocorticosteroids on the release of prostaglandin-like substances in anaphylaxis. Agents Actions Suppl 1977 0.75
101 Pharmacology at the Jagiellonian University in Kracow, short review of contribution to global science and cardiovascular research through 400 years of history. J Physiol Pharmacol 2006 0.75
102 [Effect of etmozin on thrombocyte aggregation capacity]. Biull Eksp Biol Med 1982 0.75
103 [In memoriam: Dr. Alfons Mackowski]. Pol Przegl Chir 1973 0.75